The association between antihypertensive drugs and glioma

We pursued an association between hypertension and gliomas by investigating whether antihypertensive drugs (AHD) are associated with an increased glioma risk by a population-based nested case–control study using the PHARMO database; this links dispensing records of prescription drugs to hospital dis...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2006-03, Vol.94 (5), p.752-756
Main Authors: Houben, M P W A, Coebergh, J W W, Herings, R M C, Casparie, M K, Tijssen, C C, van Duijn, C M, Stricker, B H Ch
Format: Article
Language:English
Subjects:
Adult
Aged
Antihypertensive Agents - adverse effects
Antihypertensive Agents - therapeutic use
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Brain cancer
Brain Neoplasms - epidemiology
Brain Neoplasms - etiology
Cancer Research
Case-Control Studies
Drug Resistance
Drug stores
Epidemiology
Female
Glioma - epidemiology
Glioma - etiology
Humans
Male
Medical sciences
Middle Aged
Molecular Medicine
Netherlands - epidemiology
Neurology
Oncology
Pharmacists
Prescription drugs
Risk Factors
Tumors
Tumors of the nervous system. Phacomatoses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We pursued an association between hypertension and gliomas by investigating whether antihypertensive drugs (AHD) are associated with an increased glioma risk by a population-based nested case–control study using the PHARMO database; this links dispensing records of prescription drugs to hospital discharge data on an individual basis. Pathological data were derived from the Dutch nationwide registry of histo- and cytopathology. A total of 306 glioma cases incident between 1997 and 2003 were matched to 1108 controls for year of birth, sex, geographical region and duration of follow-up. Exposure was defined as cumulative duration of AHD use and, in an alternative analysis, as cumulative dose. We estimated the magnitude of the association with conditional logistic regression analysis. Cumulative use of any AHD for more than 6 months was associated with an increased risk of glioma (OR 1.45; 95% CI 1.03–2.04). After stratification for different groups of AHD, no significantly increased risk of glioma was found for any class of AHD. After excluding a latency period of 3 years before the date of diagnosis, no association was found. In conclusion, the use of AHD seems to be associated with an increased risk of glioma, but this is probably not causal.
ISSN:0007-0920
1532-1827
DOI:10.1038/sj.bjc.6603000